QbD elements missing during regulatory review – how to redesign formulation strategy
Identifying Missing QbD Elements During Regulatory Review and Redesigning Formulation Strategy In the pharmaceutical sector, the absence of Quality by Design (QbD) elements during regulatory reviews can lead to significant…